The facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
WuXi AppTec announced on March 10, 2020 that it has resumed operations at its Wuhan, China, site in agreement with local regulations and global novel coronavirus (COVID-19) health and safety guidelines.
According to a company press release, the facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
“We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible,” said Steve Yang, executive vice-president and chief business officer of WuXi AppTec, in a company press release. “We value our customers’ contributions to the healthcare field and put them first by providing timely and world-class quality service and continue to do the right thing for patients-a goal that WuXi AppTec has pursued since its founding.”
Source: WuXi AppTec
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.